相关实验视频
Updated: Sep 18, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
在平坦中使用JAK抑制剂:最新情况
Dario Didona1, Raffaele Dante Caposiena Caro2, Laura Calabrese3,4
1Rare Skin Diseases Center, Istituto Dermopatico dell'Immacolata, Istituto Dermopatico dell'Immacolata-IRCCS, 00167 Rome, Italy.
Medicina (Kaunas, Lithuania)
|June 27, 2025
概括
简氏激酶 (JAK) 抑制剂在治疗长期炎症状况 - - 状平原 (LP) 方面表现有前途. 初步数据表明,它们对难以治疗的LP病例有效,具有良好的安全性.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 分子生物学分子生物学
- 临床药理学 临床药理学
背景情况:
- 平 (LP) 是一种慢性炎症疾病,具有多种临床表现和可变的治疗反应.
- 目前对抗性LP的治疗方法往往不符合标签,有效性有限.
- JAK/STAT信号通路与LP病原发生有关,涉及关键细胞因子,如干扰素-和介质蛋白-21.
研究的目的:
- 审查在LP中使用Janus激酶 (JAK) 抑制剂的生物学理由.
- 系统地总结JAK抑制剂在LP变体 (皮肤,粘膜,附属体,指甲) 的临床证据.
主要方法:
- 对调查平中的JAK抑制剂的研究进行文献综述.
- 临床结果和安全数据的系统摘要.
主要成果:
- 初步数据表明,在许多难以治疗的LP患者中,结果有利.
- 雅克抑制剂在管理LP时表现出可接受的安全性.
- 有证据支持JAK/STAT通路调节在LP治疗中的作用.
结论:
- 雅克抑制剂代表了对各种形式的平坦菌有前途的治疗选择.
- 需要进一步的前性试验来确认它们的有效性,并为LP管理制定指导方针.
相关概念视频
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Antiasthma Drugs: Leukotriene Modifiers
495
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
495
Dipeptidyl Peptidase 4 Inhibitors
270
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
270
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
259
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
259

